Search Videos and More
News
Novel Antibody-Drug Conjugate Demonstrates Durable Responses in Patients With Platinum-Resistant Ovarian Cancer
An investigational antibody-drug conjugate demonstrated clinically meaningful and durable responses in patients with platinum-resistant ovarian cancer, including patients whose tumors had low or no expression of folate receptor alpha (FRalpha), according to findings from the Phase 1/2 RAINFOL-01 clinical trial.
News
Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer
Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared to a standard combination approach.
News
Dana-Farber Researchers Find Blood Test Could Guide Future Treatment in Ewing Sarcoma
Prospective national study validates circulating tumor DNA as a predictor of relapse risk and identifies low-, intermediate-, and high-risk patient groups
News
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see. New research from Dana-Farber Cancer Institute scientists reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells and suggests a therapeutic strategy as a countermeasure: Change what the cancer displays on its surface so the immune system can recognize the tumor.
News
Building a System of Focused Care for Lobular Breast Cancer
How Dana-Farber investigators are pioneering new approaches to help understand, diagnose, and treat this distinct form of breast cancer
News
Dana-Farber Science Backs Development of Targeted Therapy for Rare GIST Cancer
Some things are best kept under lock and key, like oncogenes, which are genes that are associated with cancer growth because they signal cells to grow rapidly.
News
Targeting CDK2 Could Boost Immunotherapy Response in Patients With a Wide Range of Cancers, According to Dana-Farber Science
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could potentially be more broadly applicable to a wide range of cancers when combined with immunotherapy.
News
FDA Approves First CELMoD Agent, with Dana-Farber Helping Advance its Development
The U.S. Food and Drug Administration has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma, making it the first approved cereblon E3 ligase modulator (CELMoD) for this disease.
News
Dana-Farber Investigators Develop Protein Degrader Discovery Platform and Find First-in-Kind Metabolically Activated Molecular Glue Degrader
Investigators at Dana-Farber Cancer Institute have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates. The platform could help drug developers dramatically expand the range of disease-related proteins that can be therapeutically targeted for elimination via protein degradation.
News
Collaborative Team Doubles Number of In Vitro Patient-Derived Cancer Models Available for Research
A collaborative team led by investigators from Dana-Farber Cancer Institute and elsewhere developed 665 next-generation patient-derived cancer models across 27 common and rare forms of cancer and made the models plus relevant clinical and molecular data available as a resource to researchers around the globe to accelerate cancer advances.
News
FDA Approves Personalized Blood-Test Guided Immunotherapy for Bladder Cancer, Backed by Dana-Farber Science
When patients with bladder cancer complete treatment that is intended to cure the cancer, they may be left wondering if there is anything else they should do to keep the cancer from coming back.
News
Dana-Farber Researchers Identify CDK8 as a Potential Therapeutic Target for Alveolar Rhabdomyosarcoma
Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma (aRMS), an aggressive childhood cancer with poor survival and few targeted treatment options, to identify new treatment vulnerabilities. Using a network-based analysis of large functional genomic datasets, they found that aRMS cells depend on CDK8, a protein involved in controlling gene activity.